{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:03:14Z","timestamp":1793775794488,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-003"],"award-info":[{"award-number":["2021-I2M-1-003"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-061"],"award-info":[{"award-number":["2021-I2M-1-061"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-A-003"],"award-info":[{"award-number":["2022-I2M-C&T-A-003"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["Y-HR2020QN-0414"],"award-info":[{"award-number":["Y-HR2020QN-0414"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["Y-HR2020MS-0415"],"award-info":[{"award-number":["Y-HR2020MS-0415"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["Y-HR2019-0239"],"award-info":[{"award-number":["Y-HR2019-0239"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-128"],"award-info":[{"award-number":["2022-PUMCH-B-128"]}]},{"name":"CSCO-MSD Cancer Research Fund","award":["Y-MSDZD2021-0213"],"award-info":[{"award-number":["Y-MSDZD2021-0213"]}]},{"DOI":"10.13039\/501100018538","name":"National Ten-thousand Talent Program","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100018538","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Accumulating evidence suggests that the gut microbiota and metabolites can modulate tumor responses to immunotherapy; however, limited data has been reported on biliary tract cancer (BTC). This study used metagenomics and metabolomics to identify characteristics of the gut microbiome and metabolites in immunotherapy-treated BTC and their potential as prognostic and predictive biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective cohort study enrolled 88 patients with BTC who received PD-1\/PD-L1 inhibitors from November 2018 to May 2022. The microbiota and metabolites significantly enriched in different immunotherapy response groups were identified through metagenomics and LC-MS\/MS. Associations between microbiota and metabolites, microbiota and clinical factors, and metabolites and clinical factors were explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Significantly different bacteria and their metabolites were both identified in the durable clinical benefit (DCB) and non-durable clinical benefit (NDB) groups. Of these, 20 bacteria and two metabolites were significantly associated with survival. <jats:italic>Alistipes<\/jats:italic> were positively correlated with survival, while <jats:italic>Bacilli<\/jats:italic>, <jats:italic>Lactobacillales<\/jats:italic>, and Pyrrolidine were negatively correlated with survival. Predictive models based on six bacteria, four metabolites, and the combination of three bacteria and two metabolites could all discriminated between patients in the DCB and NDB groups with high accuracy. Beta diversity between two groups was significantly different, and the composition varied with differences in the use of immunotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with BTC receiving immunotherapy have specific alterations in the interactions between microbiota and metabolites. These findings suggest that gut microbiota and metabolites are potential prognostic and predictive biomarkers for clinical outcomes of anti-PD-1\/PD-L1-treated BTC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40364-024-00607-8","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:02:54Z","timestamp":1717434174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Gut microbiota and metabolites signatures of clinical response in anti-PD-1\/PD-L1 based immunotherapy of biliary tract cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Chengpei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Xun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuo","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinting","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianzhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"607_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"607_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet"},{"issue":"1","key":"607_CR3","doi-asserted-by":"publisher","first-page":"100378","DOI":"10.1016\/j.esmoop.2021.100378","volume":"7","author":"A Lamarca","year":"2022","unstructured":"Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open. 2022;7(1):100378. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100378","journal-title":"ESMO Open"},{"key":"607_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","volume":"40","author":"MD Vesely","year":"2022","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45\u201374. https:\/\/doi.org\/10.1146\/annurev-immunol-070621-030155","journal-title":"Annu Rev Immunol"},{"key":"607_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15:143. https:\/\/doi.org\/10.1186\/s13045-022-01362-9","journal-title":"J Hematol Oncol"},{"key":"607_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","volume":"40","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40:378\u2013378. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.378","journal-title":"J Clin Oncol"},{"key":"607_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-021-00923-w","volume":"13","author":"E Hayase","year":"2021","unstructured":"Hayase E, Jenq RR. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med. 2021;13:107. https:\/\/doi.org\/10.1186\/s13073-021-00923-w","journal-title":"Genome Med"},{"key":"607_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","volume":"15","author":"Y Lu","year":"2022","unstructured":"Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022;15:47. https:\/\/doi.org\/10.1186\/s13045-022-01273-9","journal-title":"J Hematol Oncol"},{"key":"607_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"607_CR10","doi-asserted-by":"publisher","unstructured":"Kovtonyuk LV, McCoy KD. Microbial metabolites and immunotherapy: basic rationale and clinical indications. Semin Immunol. 2023;101755. https:\/\/doi.org\/10.1016\/j.smim.2023.101755","DOI":"10.1016\/j.smim.2023.101755"},{"key":"607_CR11","doi-asserted-by":"publisher","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","volume":"9","author":"J Mao","year":"2021","unstructured":"Mao J, Wang D, Long J, Yang X, Lin J, Song Y, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer. 2021;9:e003334. https:\/\/doi.org\/10.1136\/jitc-2021-003334","journal-title":"J Immunother Cancer"},{"key":"607_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1 \u2013 standardisation and disease-specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer. 2016;62:138\u201345. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.082","journal-title":"Eur J Cancer"},{"key":"607_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348:124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"key":"607_CR14","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884\u201390. https:\/\/doi.org\/10.1093\/bioinformatics\/bty560","journal-title":"Bioinformatics"},{"key":"607_CR15","doi-asserted-by":"publisher","first-page":"D670","DOI":"10.1093\/nar\/gku1177","volume":"43","author":"KR Rosenbloom","year":"2015","unstructured":"Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M, et al. The UCSC Genome Browser database: 2015 update. Nucleic Acids Res. 2015;43:D670\u201381. https:\/\/doi.org\/10.1093\/nar\/gku1177","journal-title":"Nucleic Acids Res"},{"key":"607_CR16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/nmeth.3589","volume":"12","author":"Truong","year":"2015","unstructured":"Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat Methods. 2015;12:902\u20133. https:\/\/doi.org\/10.1038\/nmeth.3589","journal-title":"Nat Methods"},{"key":"607_CR17","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41592-018-0176-y","volume":"15","author":"EA Franzosa","year":"2018","unstructured":"Franzosa EA, McIver LJ, Rahnavard G, Thompson LR, Schirmer M, Weingart G, et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods. 2018;15:962\u20138. https:\/\/doi.org\/10.1038\/s41592-018-0176-y","journal-title":"Nat Methods"},{"key":"607_CR18","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/bioinformatics\/btn323","volume":"24","author":"D Kessner","year":"2008","unstructured":"Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008;24:2534\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btn323","journal-title":"Bioinformatics"},{"key":"607_CR19","unstructured":"Oksanen J, Blanchet FG, Friendly M. Vegan: community ecology package, 2019. Available: https:\/\/CRAN.R-project.org\/package=vegan"},{"key":"607_CR20","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1038\/ncomms7528","volume":"116","author":"Q Feng","year":"2015","unstructured":"Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;116:6528. https:\/\/doi.org\/10.1038\/ncomms7528","journal-title":"Nat Commun"},{"key":"607_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40425-019-0574-4","volume":"7","author":"J Fessler","year":"2019","unstructured":"Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019;7:108. https:\/\/doi.org\/10.1186\/s40425-019-0574-4","journal-title":"J Immunother Cancer"},{"key":"607_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/imr.12584","volume":"279","author":"O Pabst","year":"2017","unstructured":"Pabst O. Correlation, consequence, and functionality in microbiome-immune interplay. Immunol Rev. 2017;279:4\u20137. https:\/\/doi.org\/10.1111\/imr.12584","journal-title":"Immunol Rev"},{"key":"607_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/imm.12930","volume":"154","author":"CH Kim","year":"2018","unstructured":"Kim CH. Immune regulation by microbiome metabolites. Immunology. 2018;154:220\u20139. https:\/\/doi.org\/10.1111\/imm.12930","journal-title":"Immunology"},{"key":"607_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41571-023-00785-8","volume":"20","author":"AM Thomas","year":"2023","unstructured":"Thomas AM, Fidelle M, Routy B, Kroemer G, Wargo JA, Segata N, et al. Gut OncoMicrobiome signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol. 2023;20:583\u2013603. https:\/\/doi.org\/10.1038\/s41571-023-00785-8","journal-title":"Nat Rev Clin Oncol"},{"key":"607_CR25","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019;14:1378\u201389. https:\/\/doi.org\/10.1016\/j.jtho.2019.04.007","journal-title":"J Thorac Oncol"},{"key":"607_CR26","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368\u201379. https:\/\/doi.org\/10.1093\/annonc\/mdx108","journal-title":"Ann Oncol"},{"key":"607_CR27","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1158\/1078-0432.CCR-20-4834","volume":"27","author":"FY Shaikh","year":"2021","unstructured":"Shaikh FY, White JR, Gills JJ, Hakozaki T, Richard C, Routy B, et al. A Uniform Computational Approach Improved on existing pipelines to reveal Microbiome biomarkers of nonresponse to Immune Checkpoint inhibitors. Clin Cancer Res. 2021;27:2571\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4834","journal-title":"Clin Cancer Res"},{"key":"607_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104\u20138. https:\/\/doi.org\/10.1126\/science.aao3290","journal-title":"Science"},{"key":"607_CR29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"key":"607_CR30","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/2326-6066.CIR-20-0196","volume":"8","author":"T Hakozaki","year":"2020","unstructured":"Hakozaki T, Richard C, Elkrief A, Hosomi Y, Benla\u00effaoui M, Mimpen I, et al. The Gut Microbiome Associates with Immune Checkpoint Inhibition outcomes in patients with Advanced Non-small Cell Lung Cancer. Cancer Immunol Res. 2020;8:1243\u201350. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0196","journal-title":"Cancer Immunol Res"},{"key":"607_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunotherapy Cancer. 2019;7:193. https:\/\/doi.org\/10.1186\/s40425-019-0650-9","journal-title":"J Immunotherapy Cancer"},{"key":"607_CR32","doi-asserted-by":"publisher","first-page":"e140940","DOI":"10.1172\/jci.insight.140940","volume":"5","author":"A Limeta","year":"2020","unstructured":"Limeta A, Ji B, Levin M, Gatto F, Nielsen J. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight. 2020;5:e140940. https:\/\/doi.org\/10.1172\/jci.insight.140940","journal-title":"JCI Insight"},{"key":"607_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","volume":"78","author":"L Derosa","year":"2020","unstructured":"Derosa L, Routy B, Fidelle M, Iebba V, Alla L, Pasolli E, et al. Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients. Eur Urol. 2020;78:195\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.044","journal-title":"Eur Urol"},{"key":"607_CR34","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","volume":"5","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019;5:1774\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2785","journal-title":"JAMA Oncol"},{"key":"607_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.euo.2019.09.001","volume":"3","author":"A-KA Lalani","year":"2020","unstructured":"Lalani A-KA, Xie W, Braun DA, Kaymakcalan M, Boss\u00e9 D, Steinharter JA, et al. Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. Eur Urol Oncol. 2020;3:372\u201381. https:\/\/doi.org\/10.1016\/j.euo.2019.09.001","journal-title":"Eur Urol Oncol"},{"key":"607_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/ijc.34118","volume":"151","author":"H Wu","year":"2022","unstructured":"Wu H, Zheng X, Pan T, Yang X, Chen X, Zhang B, et al. Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma. Int J Cancer. 2022;151:1321\u201334. https:\/\/doi.org\/10.1002\/ijc.34118","journal-title":"Int J Cancer"},{"key":"607_CR37","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.3390\/cancers14215369","volume":"14","author":"B Pietrzak","year":"2022","unstructured":"Pietrzak B, Tomela K, Olejnik-Schmidt A, Galus \u0141, Mackiewicz J, Kaczmarek M, et al. A clinical outcome of the anti-PD-1 therapy of melanoma in Polish patients is mediated by population-specific gut microbiome composition. Cancers. 2022;14:5369. https:\/\/doi.org\/10.3390\/cancers14215369","journal-title":"Cancers"},{"key":"607_CR38","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3390\/jcm12062216","volume":"12","author":"J An","year":"2023","unstructured":"An J, Kwon H, Kim YJ. The Firmicutes\/Bacteroidetes ratio as a risk factor of breast cancer. J Clin Med. 2023;12:2216. https:\/\/doi.org\/10.3390\/jcm12062216","journal-title":"J Clin Med"},{"key":"607_CR39","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41598-023-29136-4","volume":"13","author":"Y Haberman","year":"2023","unstructured":"Haberman Y, Kamer I, Amir A, Goldenberg S, Efroni G, Daniel-Meshulam I, et al. Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit. Sci Rep. 2023;13:2007. https:\/\/doi.org\/10.1038\/s41598-023-29136-4","journal-title":"Sci Rep"},{"key":"607_CR40","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/2050640618804444","volume":"6","author":"M Rau","year":"2018","unstructured":"Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United Eur Gastroenterol J. 2018;6:1496\u2013507. https:\/\/doi.org\/10.1177\/2050640618804444","journal-title":"United Eur Gastroenterol J"},{"key":"607_CR41","doi-asserted-by":"publisher","first-page":"812882","DOI":"10.3389\/fphys.2021.812882","volume":"12","author":"JB Warner","year":"2022","unstructured":"Warner JB, Larsen IS, Hardesty JE, Song YL, Warner DR, McClain CJ, et al. Human beta defensin 2 ameliorated alcohol-associated liver disease in mice. Front Physiol. 2022;12:812882. https:\/\/doi.org\/10.3389\/fphys.2021.812882","journal-title":"Front Physiol"},{"key":"607_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.chom.2016.03.007","volume":"19","author":"AR Moschen","year":"2016","unstructured":"Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph TE, Reider SJ, et al. Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. Cell Host Microbe. 2016;19:455\u201369. https:\/\/doi.org\/10.1016\/j.chom.2016.03.007","journal-title":"Cell Host Microbe"},{"key":"607_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41588-021-00968-y","volume":"54","author":"X Liu","year":"2022","unstructured":"Liu X, Tong X, Zou Y, Lin X, Zhao H, Tian L, et al. Mendelian randomization analyses support causal relationships between blood metabolites and the gut microbiome. Nat Genet. 2022;54:52\u201361. https:\/\/doi.org\/10.1038\/s41588-021-00968-y","journal-title":"Nat Genet"},{"key":"607_CR44","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AEM.03473-15","volume":"82","author":"O Polansky","year":"2016","unstructured":"Polansky O, Sekelova Z, Faldynova M, Sebkova A, Sisak F, Rychlik I. Important metabolic pathways and biological processes expressed by chicken cecal microbiota. Appl Environ Microbiol. 2016;82:1569\u201376. https:\/\/doi.org\/10.1128\/AEM.03473-15","journal-title":"Appl Environ Microbiol"},{"key":"607_CR45","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3389\/fmicb.2017.02166","volume":"8","author":"H Kaur","year":"2017","unstructured":"Kaur H, Das C, Mande SS. In silico analysis of putrefaction pathways in bacteria and its implication in colorectal cancer. Front Microbiol. 2017;8:2166. https:\/\/doi.org\/10.3389\/fmicb.2017.02166","journal-title":"Front Microbiol"},{"key":"607_CR46","doi-asserted-by":"publisher","first-page":"E1306","DOI":"10.1073\/pnas.1518189113","volume":"113","author":"J Li","year":"2016","unstructured":"Li J, Sung CY, Lee N, Ni Y, Pihlajam\u00e4ki J, Panagiotou G, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016;113:E1306\u201315. https:\/\/doi.org\/10.1073\/pnas.1518189113","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-024-00607-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-024-00607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T17:05:00Z","timestamp":1717434300000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-024-00607-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["607"],"URL":"https:\/\/doi.org\/10.1186\/s40364-024-00607-8","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board and Ethics Committee of Peking Union Medical College Hospital (PUMCH, IRB NO. JS-2296). All participants gave written consent before inclusion, and the study protocol adheres to the ethical guidelines of the 1975 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}